Check out this video on
@NKF
featuring NBA star Alonzo Mourning and his nephrologist, Dr. Gerald Appel, who discussed Alonzo’s journey with APOL1-mediated
#KidneyDisease
. Alonzo Mourning is a paid spokesperson for Vertex Pharmaceuticals. Watch here:
It's important for physicians to be aware of APOL1-mediated kidney disease (AMKD) and how to be proactive about detecting it. Vertex’s Dr. Ogo Egbuna and 🏀 Hall-of-Famer
@iamzo33
are presenting at
#NMANOLA23
to raise awareness. Learn more about AMKD at .
The
#CysticFibrosis
(CF) community is what drives us to do all that we can to research & develop the next generation of therapies for people living with CF. This month, & always, we remain steadfast in our pursuit.
#CFAwarenessMonth
#GoingtheDistanceinCF
Our dedication to the cystic fibrosis (CF) community extends beyond our research & development efforts. Vertex funds innovative patient-centric programs that support people with CF to live fuller, more engaged lifestyles through our Circle of Care grant:
Our scientists don’t see the impossible as an obstacle, they see it as a good place to start. Listen to Fred Van Goor, VP, CF Research, talk about our commitment to pursuing new therapeutic advances for people living with
#CysticFibrosis
#GoingtheDistanceinCF
Gene editing is being researched to treat many genetic disorders. One method allows for cells to be carefully edited outside of the body, or ex vivo. Watch the animation to learn more about this innovative technique.
Vertex’s Health Economics and Outcomes Research team is looking forward to sharing their poster presentation on the societal burden of opioid use at
#PAINWeek
2023.
Our journey in discovering treatments for certain rare diseases began more than two decades ago with
#CysticFibrosis
. Since then, we’ve remained true to science & continue to work tirelessly toward reaching all people with CF. Learn more about our history and path forward in CF.
Visit to read a debrief of
#ASGCT21
by our Chief of Cell and Genetic Therapies, Bastiano Sanna. We were excited to sponsor and present our work in the area at
@ASGCTherapy
's virtual meeting.
Listen to Rebecca Hunt, Vice President of Patient & Community Engagement talk about our commitment to
#GoingtheDistanceinCF
for the community that has been there at every step of our 20+ year journey :
Our work in type 1 diabetes (T1D) began with two parents learning to manage a lifelong disease that their son was born with. Hear the story of Doug Melton, whose family inspired him to turn his research towards approaches for potential treatments for T1D.
🏀 hall-of-famer Alonzo Mourning was featured on
@nbc6
to talk about his journey with APOL1-mediated kidney disease. Watch this video to hear him talk about his experience. Alonzo Mourning is a paid spokesperson for Vertex Pharmaceuticals.
It was a privilege to attend
@FundSickleCell
’s 17th Annual Sickle Cell Disease Research & Education Symposium to hear about scientific advances in
#SCD
. Learn more:
Patients are the “why” behind our work at Vertex. This November, we’re proud to support the many patients, families and caregivers affected by alpha-1 antitrypsin deficiency (AATD) to help raise awareness and amplify the voices of alpha-1 community.
#Alpha1AwarenessMonth
Our work in type 1 diabetes (T1D) was inspired by two parents learning to manage a lifelong disease their son was born with. Hear from Dr. Doug Melton, whose family motivated him to turn his research toward potential new treatments for T1D.
#DiabetesAwarenessMonth
It’s
#NationalKidneyMonth
, and we’re proud to amplify the stories of those affected by APOL1-mediated
#KidneyDisease
(AMKD). Check out this animated video to hear from Dr. Kendra Richardson (who is living with AMKD) and learn about her journey to a diagnosis.
Our journey in discovering treatments for certain rare diseases began more than two decades ago with
#CysticFibrosis
. Since then, we’ve remained true to science & continue to work tirelessly toward reaching all people with CF. Learn more about our history & path forward in CF.
Our global team is working tirelessly with the goal of helping people living with
#Pain
. It’s our privilege to join the community in recognizing September as
#PainAwarenessMonth
.
Listen to Rebecca Hunt, Vice President of Patient & Community Engagement talk about our commitment to
#GoingtheDistanceinCF
for the community that has been there at every step of our 20+ year journey:
Want to learn how a genetic therapy is manufactured? Come behind the scenes with us to learn about the innovative cell and genetic therapy manufacturing process and see each of the steps involved.
November 14 is World Diabetes Day, a chance to shed light on the burdens impacting millions of people living with diabetes across the globe. Learn more in this animation:
We are proud to sponsor the 2023
@CanHaem
Annual Conference and AGM this week alongside dedicated clinicians. Hearing about advances in sickle cell disease and beta thalassemia is invigorating for our teams at Vertex!
November is
#Alpha1AwarenessMonth
, and we’re proud to join the community as we recognize the patients, caregivers and families affected by alpha-1 antitrypsin deficiency (AATD). You can learn more about
#AATD
and our research toward a potential treatment below:
At Vertex, our goal is to improve the lives of people living with serious diseases. In honor of
#InternationalThalassemiaDay
, watch this animation to learn more about the disease and our role.
#betathalassemia
As strong believers in the next generation of cystic fibrosis (CF) researchers, it is our goal to help support and inspire innovation through our Research Innovation Awards. Learn more about our CF grants programs and how to apply:
#GoingtheDistanceinCF
It was great to be a sponsor of
@CooleysAnemia
’s Patient-Family conference in Los Angeles last week to connect with and learn from people impacted by
#BetaThalassemia
. Learn more:
Our commitment to the community extends beyond drug development. Circle of Care is an annual grant opportunity that funds innovative, patient-centric programs for people with CF. Learn more and how to apply today:
#GoingtheDistanceinCF
The patient voice is integral to us at Vertex. That’s why we’re excited to attend
@diaTribenews
’s free panel discussion, “Managing Hypoglycemia & Hypo Unawareness: Is Technology Enough?” to listen & learn alongside the
#type1diabetes
community. Learn more:
It’s
#PainAwarenessMonth
, and we’re proud to support the U.S. Pain Foundation and its work to educate, empower, connect and advocate for people living with
#pain
. Stay tuned to
@US_Pain
channels this month to learn more:
At Vertex, we‘re investigating potential treatments for sickle cell disease. It’s a privilege to participate in the 10th Annual Sickle Cell Disease Therapeutics Conference this
#sicklecellawarenessmonth
alongside our peers. Learn more at:
Alongside our work researching potential treatments for APOL1-mediated
#KidneyDisease
(AMKD), we’re proud to support
@KidneyFund
& the kidney community to drive innovation in research, diagnosis & treatment of the underlying causes of kidney disease:
Pain – both common and complex –affects people differently and is influenced by things like genetics, gender, and age.
We’re thinking differently about the condition by trying to target pain where it starts. Learn how on Targeting the Toughest Diseases:
We look forward to connecting with attendees at
@SCCConsortium
’s 3rd Annual Sickle Cell Caregiver Summit and learning from the wonderful caregivers in the
#SickleCellDisease
community. Learn more:
Want to join a team dedicated to improving the lives of people using innovative technology such as gene and cell therapy? Come meet us at
@ASGCTherapy
’s 26th Annual Meeting at booth 841.
#ASGCT2023
Congrats to our Sr. VP of Research, Paul Negulescu, for receiving the 2022 Shaw Prize in Life Sciences in Medicine for his work in
#CF
! This award recognizes unique individuals who have recently made distinguished and significant advances in their field.
As we continue to work on potential treatments for
#type1diabetes
, it’s exciting to see this
@Nature
timeline of over 100 years of research, including contributions from Doug Melton, and Vertex’s Felicia Pagliuca and David Altshuler. Learn more:
We’re excited to sponsor this year’s
@SCDAAorg
Annual Convention in company with experts in
#sicklecelldisease
research, advocates, and warriors. Stop by our booth!
Risk variants in the APOL1 gene the cause of APOL1-mediated kidney disease – only affect people of African ancestry. Hear how scientists are using this understanding of the disease & applying it to cutting-edge research on Targeting the Toughest Diseases:
Patients are at the center of everything we do at Vertex. It’s our privilege to be sponsoring
@CooleysAnemia
’s Patient-Family Conference in Los Angeles to connect with the
#BetaThalassemia
community. Learn more:
Type 1 diabetes (T1D) needs constant vigilance, burdening caregivers & those living with this condition. For
#DiabetesAwarenessMonth
, hear from Vertex researchers Drs. Doug Melton & Felicia Pagliuca on why we are investigating the underlying cause of
#T1D
:
A new study from our Health Economics and Outcomes Research team has for the first time quantified health care prejudice experienced by people living with
#SickleCellDisease
. Learn more:
Alongside our work researching potential treatments for APOL1-mediated
#KidneyDisease
(AMKD), we’re proud to support
@KidneyFund
& the kidney community to drive innovation in research, diagnosis & treatment of the underlying causes of kidney disease:
Pain – both common and complex –affects people differently and is influenced by things like genetics, gender, and age.
We’re thinking differently about the condition by trying to target pain where it starts. Learn how on Targeting the Toughest Diseases:
As we recognize CF Awareness Month, we celebrate the progress made to advance the care for people with CF but also acknowledge the work that lies ahead in our path forward. Learn more:
#CFAwarenessMonth
#GoingtheDistanceinCF
It was a privilege to attend the
@EASDnews
Annual Meeting last week. Our
#T1D
team was thrilled to participate alongside experts in the field as we continue our work pursuing a potential treatment for those living with
#type1diabetes
. Learn more at
We know that people with
#Type1Diabetes
are missing insulin-producing cells. Our research teams are applying our deep understanding of this causal human biology to our research, at the cellular level. Learn more:
Are you an early career physician scientist looking to make an impact? Applications are open for the next cohort of our Vertex Physician Investigators! Learn about this two-year rotational program, meet recent participants and apply now: .
Living with
#Type1Diabetes
can be a 24/7 job for people with the disease. Despite advances in managing it, there’s still no cure. This unmet need drives our investigation into
#T1D
– at a cellular level. Hear more on Targeting the Toughest Diseases:
We’re committed to inspiring the next generation of
#CysticFibrosis
research-focused PhDs and MDs through our competitive cystic fibrosis (CF) award programs. Is this you or someone you know? Apply today:
It was great to be at
@ASNKidney
’s
#KidneyWeek
to hear about research in
#KidneyDisease
and join the conversation in this space. Learn more about our research in APOL1-mediated kidney disease (AMKD) in this animated video:
It’s
#PainAwarenessMonth
, and we’re proud to join the community in recognition of the many patients, caregivers and families whose lives are affected by this debilitating disorder. Watch this video to learn more about science of
#pain
& our research toward a potential treatment:
Our Health Economics and Outcomes Research team was honored to present their latest
#HealthEquity
research findings in
#SickleCellDisease
at the 30th
@ISOQOL
Annual Conference last week.
For LiNa Loo, each data point represents another step or steering point forward in research for
#DuchenneMuscularDystrophy
. To learn more about what working in
#DMD
means to LiNa and 4 other female scientists, read more:
For Bastiano Sanna, Chief of Vertex Cell and Genetic Therapies, our commitment to serious diseases like beta thalassemia hits close to home. Read about his story and another Vertexian’s personal experience that sparked our work in
#hemoglobinopathies
.
CRISPR/Cas9 gene editing is an exciting tool that is used in our investigational program for
#sicklecelldisease
and
#betathalassemia
, two genetic blood disorders. Watch the animation below to learn how this technology works.
#CRISPR
At Vertex, our team is working tirelessly in the hopes of developing potential treatments for type 1 diabetes. It’s great to be at the
@ESOTtransplant
biennial congress this week alongside experts in the
#transplantation
field. Learn more at:
We’re excited to be at
#ACCE2023
alongside clinicians in endocrinology as we continue our work pursuing a potential treatment for those living with
#T1D
. Learn more about our programs here:
Vice President of Clinical Development for Vertex Cell and Genetic Therapies, Bill Hobbs, had the honor to discuss Vertex’s innovative approach in gene editing for sickle cell disease at
@StJudeResearch
’s event, “Sickle Cell Disease: What’s New with Transplant and Gene Therapy?”
It was an honor to be at the
#ADA2021
Scientific Sessions this week where we shared the story of our work in
#type1diabetes
. Check out the video below to hear from some of our leaders in this program.
Catch our Health Economics and Outcomes Research team at
#ISPOREurope
this week! They’ll present data on how
#SickleCellDisease
and
#BetaThalassemia
can affect productivity and how potential interventions may impact quality of life. Learn more:
Motivated by the research you heard about at
#EHA2021
? Come work at Vertex! Our teams are hard at work researching potential genetic therapies for sickle cell disease and beta thalassemia.
We’re excited to join the annual
@ESPNSociety
Scientific Meeting to learn from experts in the field as we continue our work pursuing a potential treatment for those living with APOL1-mediated kidney disease. Learn more: .
It’s our privilege to participate in today’s Coverage for Sickle Cell Disease Summit hosted by
@SickCells
to connect with the medical and patient
#sicklecell
community to hear their stories and learn how we can help make a difference. Learn more at:
Sometimes a known problem needs a bespoke solution. This mindset is what inspires our investigational approach using gene-editing technology.
Listen to the latest episode of Targeting the Toughest Diseases:
For people like Jon living with
#betathalassemia
, his weeks are controlled by the schedule of frequent blood transfusions that provide healthy donated blood. Learn about the burden of managing beta thalassemia:
This year marks the 100th anniversary of insulin’s discovery in 1921. This holds special meaning to us as we continue our work on a potential cell therapy to treat people living with
#type1diabetes
. Looking forward to the possibility of what’s yet to come.
#Insulin100
We’re working tirelessly to develop potential treatments for APOL1-mediated kidney disease (
#AMKD
). It was great to be at
@Nephcure
’s Allied Leadership Conference to hear from leaders in the
#KidneyDisease
space. Learn more:
Our teams from across the globe came together at this year’s EHA2022 Congress in Vienna, Austria. It was an invigorating experience to join our peers as we continue our work in
#SickleCellDisease
and
#BetaThalassemia
.
“The illness that my sisters and I have,
#SickleCellDisease
, is the leading cause of stroke in children.” Hear from 17-year-old Amatullah (Tully) as she recounts watching her sister experience a stroke at the age of 7 and how that shaped her own career aspirations.
Learn how we’re breaking through roadblocks and solving complex problems from our Senior Director of Instrumentation R&D, James Sinclair, in this animated video:
It’s
#SickleCellAwarenessMonth
and
#DuchenneActionMonth
! At Vertex, we're dedicated to exploring new possibilities in treating these diseases. Check out the video below to learn how CRISPR/Cas9 gene editing works.
We look forward to connecting with attendees at
@GlobalSCDN
’s 4th Global Congress on Sickle Cell Disease in Paris to hear about scientific research in the
#SCD
space.
#GCSCD2022
It’s great to be participating in Anesthesiology 2023 hosted by
@ASALifeline
to hear about
#pain
research and join the conversation. Come visit us at our booth!
It’s a privilege for us to take part in the 2nd Annual Gene Therapy for Blood Disorders Conference this week (March 9-11). We’re looking forward to learning from our peers as we continue our work on potential treatments for
#sicklecelldisease
and
#betathalassemia
We’re proud to sponsor a special
@NKF
Facebook Live event ft. 🏀 hall-of-famer Alonzo Mourning & his nephrologist, Dr. Gerald Appel, where they’ll talk about Zo’s journey with APOL1-mediated
#KidneyDisease
& more. Tune in on March 31:
#NationalKidneyMonth
At Vertex, we’re investigating the use of different tools, technologies and modalities—including small molecules—to potentially treat those living with
#pain
and other serious diseases. Check out this animation to learn more about small molecules and how they work.
We’re excited to participate at the
@JDRF
Type One Nation Summit next week, alongside caregivers, families, and individuals in the
#Type1Diabetes
community. Learn more:
This September, we’re recognizing
#SickleCellAwarenessMonth
to shine a light on the dedicated community of patients and caregivers, and the efforts around the world to help improve the lives of those with
#sicklecelldisease
. Watch the video for more.
It was so intense that I couldn’t even control myself—I couldn’t walk, I was just crying.”
Watch this video of
#Sicklecellwarrior
Tosin Ola as she shares the impact of
#sicklecelldisease
on her every day.
#ASH21
Welcome to the Vertex Science Twitter channel! Join us here to learn about our
#research
and
#science
, get updates on our pipeline, our participation in conferences around the globe and spotlights on our world-class scientists and the incredible patients we serve.